Magmaris preliminary recommendation upon commercial launch: A consensus from the expert panel on 14 April 2016

Jean Fajadet; Michael Haude; Michael Joner; Jacques Koolen; Michael Lee; Ralph Tölg; Ron Waksman

doi:10.4244/EIJV12I7A137

Magmaris preliminary recommendation upon commercial launch: A consensus from the expert panel on 14 April 2016

Jean Fajadet, Michael Haude, Michael Joner, Jacques Koolen, Michael Lee, Ralph Tölg, Ron Waksman

Clinic for Heart and Vascular Diseases

Research output: Contribution to journal › Article › peer-review

73 Scopus citations

Abstract

Bioresorbable scaffolds represent an exciting milestone in the development of coronary stent technology with the potential to substantially improve the management of patients with coronary artery disease. In an attempt to provide first recommendations for the technology, experienced experts involved in the first-in-man studies met in Zurich on the 14 April 2016 in order to reach consensus on a responsible market introduction. This document will be updated regularly as new information from clinical trials becomes available and should be understood as a review of current data, opportunities, expectations, advice, and recommendations for future investigations.

Original language	English
Pages (from-to)	828-833
Number of pages	6
Journal	EuroIntervention
Volume	12
Issue number	7
DOIs	https://doi.org/10.4244/EIJV12I7A137
State	Published - Sep 2016

Keywords

Bioresorbable scaffolds

Access to Document

10.4244/EIJV12I7A137

Cite this

@article{737251007a274c9690901d4b0737912b,

title = "Magmaris preliminary recommendation upon commercial launch: A consensus from the expert panel on 14 April 2016",

abstract = "Bioresorbable scaffolds represent an exciting milestone in the development of coronary stent technology with the potential to substantially improve the management of patients with coronary artery disease. In an attempt to provide first recommendations for the technology, experienced experts involved in the first-in-man studies met in Zurich on the 14 April 2016 in order to reach consensus on a responsible market introduction. This document will be updated regularly as new information from clinical trials becomes available and should be understood as a review of current data, opportunities, expectations, advice, and recommendations for future investigations.",

keywords = "Bioresorbable scaffolds",

author = "Jean Fajadet and Michael Haude and Michael Joner and Jacques Koolen and Michael Lee and Ralph T{\"o}lg and Ron Waksman",

year = "2016",

month = sep,

doi = "10.4244/EIJV12I7A137",

language = "English",

volume = "12",

pages = "828--833",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "Europa Group",

number = "7",

}

TY - JOUR

T1 - Magmaris preliminary recommendation upon commercial launch

T2 - A consensus from the expert panel on 14 April 2016

AU - Fajadet, Jean

AU - Haude, Michael

AU - Joner, Michael

AU - Koolen, Jacques

AU - Lee, Michael

AU - Tölg, Ralph

AU - Waksman, Ron

PY - 2016/9

Y1 - 2016/9

N2 - Bioresorbable scaffolds represent an exciting milestone in the development of coronary stent technology with the potential to substantially improve the management of patients with coronary artery disease. In an attempt to provide first recommendations for the technology, experienced experts involved in the first-in-man studies met in Zurich on the 14 April 2016 in order to reach consensus on a responsible market introduction. This document will be updated regularly as new information from clinical trials becomes available and should be understood as a review of current data, opportunities, expectations, advice, and recommendations for future investigations.

AB - Bioresorbable scaffolds represent an exciting milestone in the development of coronary stent technology with the potential to substantially improve the management of patients with coronary artery disease. In an attempt to provide first recommendations for the technology, experienced experts involved in the first-in-man studies met in Zurich on the 14 April 2016 in order to reach consensus on a responsible market introduction. This document will be updated regularly as new information from clinical trials becomes available and should be understood as a review of current data, opportunities, expectations, advice, and recommendations for future investigations.

KW - Bioresorbable scaffolds

UR - http://www.scopus.com/inward/record.url?scp=84991010784&partnerID=8YFLogxK

U2 - 10.4244/EIJV12I7A137

DO - 10.4244/EIJV12I7A137

M3 - Article

C2 - 27639734

AN - SCOPUS:84991010784

SN - 1774-024X

VL - 12

SP - 828

EP - 833

JO - EuroIntervention

JF - EuroIntervention

IS - 7

ER -

Magmaris preliminary recommendation upon commercial launch: A consensus from the expert panel on 14 April 2016

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this